EQ Inc is a provider of digital marketing services. It operates in a single segment, which is to provide real-time technology and advanced analytics to improve performance for web, mobile, social, and video advertising initiatives and focuses on targeted advertising and incorporates advertising technologies, data analytics, and programmatic media buying capabilities into a single segment. EQ's geographical segments are Canada and the United States, of which the vast majority of its revenue comes from Canada. It generates the highest revenue from Advertising Services, followed by Data sales, which includes fixed CPM data and licenses.
相关临床试验
9
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
进行中（未招募）
4
44.4%
已完成
3
33.3%
终止
1
11.1%
撤回
1
11.1%
暂无批准数据
- A comprehensive 2025 clinical trials review reveals the current global research landscape for alopecia universalis, analyzing trial distribution across regions, phases, and sponsor types. - Major pharmaceutical companies including Pfizer, Johnson & Johnson, Roche, and Aclaris Therapeutics are actively participating in alopecia universalis therapeutic development programs. - The report provides critical insights into trial enrollment trends over the past five years and identifies prominent drugs currently in development for this severe autoimmune hair loss condition. - Clinical trial data is compiled from over 80 different registries worldwide, offering stakeholders comprehensive market intelligence for strategic decision-making in dermatology therapeutics.
- Itolizumab demonstrated a 23.3% clinical remission rate in moderate to severe ulcerative colitis patients after 12 weeks, comparable to adalimumab's 20.0% and superior to placebo's 10.0%. - The novel CD6-ALCAM pathway targeting drug achieved 16.7% endoscopic remission, matching adalimumab's performance while maintaining a favorable safety profile. - The Phase 2 trial involved 90 biologic-naïve patients, with itolizumab showing efficacy despite having more severe cases in its treatment arm compared to control groups.
- Vivtex and Equillium have entered a research agreement to develop an oral formulation of EQ302, a bispecific peptide therapy targeting IL-15 and IL-21. - Vivtex will apply its GI-ORIS™ technology to enhance the oral bioavailability of EQ302 for treating gastrointestinal inflammation. - Equillium plans to initiate a Phase 1 clinical trial of the oral EQ302 formulation in the second half of 2025. - The collaboration aims to provide a more convenient and effective treatment option for patients with inflammatory bowel disease and other GI disorders.
